Efficacy and safety of IFX-1, an anti-C5a monoclonal antibody, in an open label Phase 2a study in patients with severe hidradenitis suppurativa (HS) not eligible for adalimumab

Giamarellos-Bourboulis E.; Argyropoulou M.; Kanni T.; Kopka I.; Zenker O.

首页> 外文期刊>Experimental dermatology >Efficacy and safety of IFX-1, an anti-C5a monoclonal antibody, in an open label Phase 2a study in patients with severe hidradenitis suppurativa (HS) not eligible for adalimumab

【24h】

Efficacy and safety of IFX-1, an anti-C5a monoclonal antibody, in an open label Phase 2a study in patients with severe hidradenitis suppurativa (HS) not eligible for adalimumab

机译：IFX-1的疗效和安全性，抗C5a单克隆抗体，在患有严重HIDradenenisapsucativa（HS）患者的开放标记相2A研究中，没有资格获得Adalimalab

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Experimental dermatology》 |2018年第s1期|共1页
作者
Giamarellos-Bourboulis E.; Argyropoulou M.; Kanni T.; Kopka I.; Zenker O.;
展开▼
作者单位

Univ Athens Dept Internal Med 4 Athens Greece;

Univ Athens Dept Internal Med 4 Athens Greece;

Univ Athens Dept Internal Med 4 Athens Greece;

Univ Athens Dept Internal Med 4 Athens Greece;

Univ Athens Dept Internal Med 4 Athens Greece;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类皮肤病学与性病学;
关键词

相似文献

外文文献

1. Efficacy and safety of IFX-1, an anti-C5a monoclonal antibody, in an open label Phase 2a study in patients with severe hidradenitis suppurativa (HS) not eligible for adalimumab [J] . Giamarellos-Bourboulis E., Argyropoulou M., Kanni T., Experimental dermatology . 2018,第S1期

机译：IFX-1的疗效和安全性，抗C5a单克隆抗体，在患有严重HIDradenenisapsucativa（HS）患者的开放标记相2A研究中，没有资格获得Adalimalab
2. Long-term adalimumab efficacy in patients with moderate-to-severe hidradenitis suppurativa/acne inversa: 3-year results of a phase 3 open-label extension study [J] . Zouboulis Christos C., Okun Martin M., Prens Errol P., Journal of the American Academy of Dermatology . 2019,第1期

机译：中度至严重的HIDradenitis的患者的长期服用疗效，Suppurativa /痤疮逆变：3年的阶段开放标签扩展研究结果
3. IFX-1 in patients with moderate to severe hidradenitis suppurativa/acne inversa (HS): baseline characteristics of a double-blind, randomized phase 2b dose-finding study (SHINE) [J] . Giamarellos-Bourboulis E. J., Henneberg J., Otto I., Experimental dermatology . 2019,第S2期

机译：IFX-1在中度至重度HIDradenitis的患者中，Suppurativa /痤疮逆（HS）：双盲的基线特征，随机相2b剂量查找研究（Shine）
4. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
5. Efficacy and safety of the fully human anti-tumour necrosis factor α monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week phase II study [O] . L B A van de Putte, R Rau, F Breedveld, 2003

机译：完全人类抗肿瘤坏死因子α单克隆抗体阿达木单抗（D2E7）在DMARD难治性类风湿关节炎患者中的疗效和安全性：一项为期12周的II期研究
6. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis:Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial [O] . Blauvelt, Andrew, Papp, Kim A, Griffiths, Christopher E M, 2017

机译：guerkumab（一种抗白细胞介素-23单克隆抗体）与阿达木单抗相比，用于持续治疗中重度银屑病患者的疗效和安全性：来自III期，双盲，安慰剂和有效比较物控制的VOYaGE 1试验的结果

Efficacy and safety of IFX-1, an anti-C5a monoclonal antibody, in an open label Phase 2a study in patients with severe hidradenitis suppurativa (HS) not eligible for adalimumab

著录项

相似文献

相关主题

期刊订阅